Press Releases

Tower Cold Chain Accelerates Growth with Two New Senior Appointments for The Americas

Following the opening of its new Centre of Excellence facility to support further growth across the Americas, advanced temperature-controlled container specialist, Tower Cold Chain, has continued the expansion of its global team with the appointment of two senior leaders.

X-Chem and Structural Genomics Consortium Enter Into Collaboration to Unlock the Human Proteome and Promote Open Science

X-Chem, a global leader in innovative drug discovery services, and the Structural Genomics Consortium (SGC), a public-private partnership dedicated to accelerating drug discovery through open science, announced that they have entered a collaboration aimed at creating new chemical tools to study human proteins.

Creative Proteomics Leads the Way with Cutting-Edge RNA Pull Down Service

Creative Proteomics Introduces Mature Solutions for Membrane Protein Identification

Evecxia Therapeutics and Quotient Sciences Complete Phase I Clinical Milestone for New Depression Treatment

Creative Proteomics Launches State-of-the-Art Peptide Sequencing Service to Advance Proteomics Research

Cytel continues expansion of market access and medical communication capabilities with the acquisition of co.faktor

Cytel Inc. has acquired the Berlin-based company co.faktor GmbH.

Discovery Park selects 13 start-ups to join Discovery Spark life science programme

Thirteen life science start-ups have been accepted onto Discovery Park’s new business support programme and competition, Discovery Spark. The eight-week Discovery Spark programme will equip the early-stage companies with the necessary skills to catalyse their business growth plans and gives them the chance to win a business support package worth over £100,000.

Announcing Kivo GO: An intuitive DMS to accelerate speed-to-market for life sciences

Kivo today introduced Kivo GO, a unified platform for emerging life sciences teams who need to work together efficiently across all functions while maintaining compliance and security.

Sygnature Discovery successfully identifies potent SHP2 degrader compounds in collaboration with UBE Corporation

Creative Biostructure Announces New Method for Producing CRAL-TRIO Domain-Containing Proteins Using Virus-Like Particles

Creative Enzymes Launches Diamine Oxidase (Food-Grade) for Enhanced Food Safety and Digestive Health

Creative Enzymes Unveils Custom Blends Product Line for Bioprocessing Solutions

CD Genomics Redefines RNA Sequencing with Revolutionary Ultra Low RNA Sequencing Technology

Macleaya cordata Extract and Analysis Service Now Available at Lifeasible

CD Genomics Unveils Cutting-Edge DNA 6mA Sequencing Service for Epigenomic Research

Matexcel Launches New Line of Natural Extract Peptide Products for Research Use

Expanding Research Frontiers: CD Formulation Enables In Vitro Cytotoxicity Testing for Microspheres and Microneedles

Alfa Chemistry: Transforming Research Possibilities through Instrumental Analytical Reagents

NICE RECOMMENDS LILLY’S MIRIKIZUMAB (OMVOH ®▼) FOR THE TREATMENT OF ELIGIBLE ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

Mirikizumab is the first IL-23p19 targeted biologic recommended by NICE for use within NHS England and Wales for treating moderately to severely active ulcerative colitis in adults.1,2. In two randomised, double-blind, placebo-controlled phase 3 trials, LUCENT-1 and LUCENT-2, mirikizumab achieved primary and key secondary endpoints, including sustained clinical remission. Decreases in bowel urgency severity were observed as early as week 2 in patients treated with mirikizumab versus placebo in LUCENT-1.2 Mirikizumab has been recommended through the NICE cost-comparison process meaning NHS England and commissioning groups have agreed to provide funding to implement this guidance within 30 days from publication of the technology appraisal guidance (TAG) rather than the standard 90 days, providing faster access to a new treatment option for eligible adults living with moderately to severely active ulcerative colitis1